Dr. Reddy's Biosimilar Ambition
India-based drug makers, who have built themselves into regional powerhouses thanks to their efforts in creating small molecules generics, are keenly interested in the biosimilar opportunity. But none has been as aggressive-or as brash - as Dr. Reddy's Laboratories. (This is a sidebar to the article "Opening A Door To Biosimilars In the US."
You may also be interested in...
With the regulatory door ajar, companies across the pharmaceutical industry are vying to dominate the biosimilars space, despite the commercial risks.
Federal law requiring agencies to weigh and document potential environmental impacts of major regulatory actions does not dictate what happens next. Neither does it provide federal agencies with authorities beyond their statutory purviews, FDA/CDER leadership says.
The European Medicines Agency has reported progress with a collaborative project that involves other regulators in its assessments of COVID-19 products, and with the EU Medicines for All initiative for evaluating products for non-EU markets.